Semaglutide vs Peptides for Weight Loss: What Actually Works?

"Should I use peptides instead of Ozempic?" is one of the most common questions on weight-loss forums, and the wellness industry has constructed an elaborate answer: sermorelin "stimulates your own GH," tesamorelin "targets visceral fat," AOD-9604 is "a fat-burning fragment of HGH," BPC-157 "heals and recomps," 5-Amino-1MQ "switches on fat metabolism." These claims sound plausible. The evidence record tells a different story. Semaglutide and tirzepatide — the GLP-1 receptor agonists at the center of the current obesity-medicine revolution — have been tested in thousands of patients across multiple large randomized controlled trials. Not one of the peptides marketed as their replacement has been tested in a human weight-loss randomized trial. This article lays out the evidence precisely: what GLP-1 drugs actually prove, what the evidence record for each marketed peptide actually contains, and why "peptides instead of Ozempic" is a marketing claim, not a clinical one.

What semaglutide and GLP-1 drugs actually prove

The STEP-1 trial (Wilding 2021 ^[1]) randomized 1,961 adults with a BMI ≥30 (or ≥27 with a weight-related comorbidity) to once-weekly subcutaneous semaglutide 2.4 mg or placebo for 68 weeks. Mean total body weight loss in the semaglutide group was −14.9% versus −2.4% on placebo. Roughly 86% of semaglutide participants achieved at least 5% weight loss, and 50% achieved at least 15%. This was the largest effect size ever documented for a pharmacological weight-loss intervention at the time of publication. The mechanism — GLP-1 receptor agonism slowing gastric emptying, reducing appetite signaling in the hypothalamus and brainstem, and improving insulin sensitivity — was well-characterized before the trial began.

SURMOUNT-1 (Jastreboff 2022 ^[2]) extended the benchmark further. This trial randomized 2,539 adults with obesity to once-weekly tirzepatide (a dual GLP-1/GIP receptor agonist) at doses of 5, 10, or 15 mg, or placebo, for 72 weeks. The 15 mg arm achieved mean total body weight loss of −20.9% versus −3.1% on placebo — a weight loss magnitude previously seen only with bariatric surgery. Across both trials, adverse events were predominantly gastrointestinal (nausea, vomiting, diarrhea) and were most pronounced during dose escalation. The safety and efficacy data from these trials underpin the FDA approvals of Wegovy (semaglutide 2.4 mg, 2021) and Zepbound (tirzepatide, 2023) for chronic weight management.

The point here is not just the magnitude of weight loss — it is the quality of evidence. STEP-1 and SURMOUNT-1 are large, pre-registered, placebo-controlled RCTs with primary weight-loss endpoints, independent adjudication, and peer review in the New England Journal of Medicine. This is the gold standard for claiming that a treatment "works" for weight loss. No peptide marketed as an alternative or complement comes close to this standard. Most have not even attempted a trial with a weight-loss primary endpoint in humans.

The peptides marketed for weight loss — and what the evidence actually shows

The peptides most commonly marketed as weight-loss tools — or as alternatives to GLP-1 drugs — fall into a few overlapping categories: growth-hormone secretagogues (sermorelin, CJC-1295, ipamorelin), a GH-releasing analogue with one narrow FDA approval (tesamorelin), a synthetic HGH fragment tested only in mice (AOD-9604), a gastric peptide with preclinical tissue-repair data (BPC-157), and a small-molecule NNMT inhibitor sold on the same grey-market sites as peptides (5-Amino-1MQ). Here is what the published human evidence actually says about each.

Sermorelin

Sermorelin is a synthetic analogue of the first 29 amino acids of growth-hormone-releasing hormone (GHRH). Its only FDA approval — Geref, for pediatric GH deficiency — has been discontinued. The weight-loss marketing extrapolates from a known relationship: GH promotes fat oxidation, so raising GH might reduce fat mass. The best available human data comes not from sermorelin itself but from a related GHRH analogue: Khorram et al. 1997 (PMID 9141536 ^[7]) ran a single-blind, randomized, placebo-controlled crossover trial of a GHRH analog in 19 age-advanced adults (10 women, 9 men, ages 55–71). After 16 weeks of nightly injections, GH and IGF-1 rose significantly. Body composition was measured by DXA. The study reported a modest reduction in fat mass and a small lean-mass increase in some subjects — but this was a 19-person crossover study in older adults, not a weight-loss RCT in people with obesity, and sermorelin itself was not the compound tested. No published human RCT has tested sermorelin with weight loss as a primary or secondary endpoint. It is not FDA-approved for obesity, weight management, or any adult indication.

BPC-157

BPC-157 (body protective compound 157) is a synthetic 15-amino-acid peptide derived from a sequence found in human gastric juice. Its preclinical rodent literature covers GI healing, tendon and ligament repair, anti-inflammatory effects, and neurological applications. Marketing for BPC-157 frequently includes weight-loss or "body recomposition" claims. The human evidence consists of early-phase IBD trial data (Sikiric et al., Inflammopharmacology 2006 ^[5] — note this reference covers BPC-157's human IND/trial history, not a weight-loss study) and a 2026 biopharmaceutical review of translational challenges. There are no published human trials of BPC-157 with weight loss, body composition, or fat mass as an endpoint. The FDA issued a warning in 2022 clarifying that compounded BPC-157 products are not legally marketed as drugs and lack the manufacturing oversight and safety review required for drug products.

Tesamorelin

Tesamorelin (Egrifta SV / Egrifta WR) is the one peptide in this group with a genuine FDA approval and a large human RCT — which is exactly why it is so important to read that RCT carefully. Falutz et al. 2007 (PMID 18057338 ^[3]) randomized 412 HIV-positive adults on antiretroviral therapy who had HIV-associated lipodystrophy (a fat redistribution syndrome causing excess visceral fat accumulation) to tesamorelin or placebo for 26 weeks. Tesamorelin reduced trunk fat area by approximately −18% versus +5% for placebo — a meaningful reduction in visceral adipose tissue in a specific metabolic disease in a specific population. Lean mass was roughly stable. The indication is not "weight loss." It is the treatment of excess abdominal fat specifically caused by HIV-related lipodystrophy. The mechanism (GHRH analogue → GH release → visceral fat mobilization) may sound relevant to obesity, but tesamorelin has not been tested in a human RCT for weight loss in people with obesity, and it is not approved for that purpose. Extrapolating the HIV-lipodystrophy data to "tesamorelin burns belly fat" in the general population is an unsupported claim.

AOD-9604

AOD-9604 is a synthetic fragment of human growth hormone (amino acid residues 176–191) with a modified tyrosine at the N-terminal end. In rodent research, Heffernan et al. 2001 (PMID 11673763 ^[6]) showed that chronic treatment with AOD-9604 increased fat oxidation and reduced body weight in obese mice by approximately 50% of the effect seen with full-length GH, apparently through a β3-adrenergic mechanism that does not raise IGF-1. This is the mechanistic foundation for the human marketing claims. What followed in humans: a phase 2 clinical development program in Australia showed no significant weight loss versus placebo in trials conducted in the early 2000s. No phase 3 trial was completed, no FDA application was filed, and AOD-9604 is not approved for any indication in any country. The rodent data exists; the human weight-loss RCT does not. AOD-9604 is currently sold as an "unscheduled research chemical" in Australia (it received a novel food designation) and as an unapproved research compound elsewhere — not as a drug.

5-Amino-1MQ

5-Amino-1MQ (5-amino-1-methylquinolinium) is not technically a peptide — it is a synthetic small molecule that inhibits nicotinamide N-methyltransferase (NNMT), an enzyme involved in cellular energy metabolism and one-carbon metabolism. It appears on peptide-marketing sites because it is sold in the same grey-market channels and targets a similar "metabolic optimization" buyer. In mouse studies, NNMT inhibition raises intracellular NAD+ and SAM levels, suppresses lipogenesis in adipose tissue, and reduces body fat in diet-induced-obese animals. There are no published human clinical trials of 5-Amino-1MQ of any kind — zero human safety data, zero human efficacy data, no weight-loss endpoint. The compound is not FDA-approved and is classified as a research chemical. See our companion article on 5-Amino-1MQ and weight loss for the full evidence review.

CJC-1295 and Ipamorelin

CJC-1295 is a long-acting GHRH analogue; ipamorelin is a selective growth-hormone secretagogue receptor (GHSR) agonist — a ghrelin mimetic. Both are commonly co-prescribed at compounding clinics as a "GH stack." The human evidence: Teichman et al. 2006 (PMID 16352683 ^[4]) showed that CJC-1295 raised GH up to 10-fold and IGF-1 by 1.5–3-fold for up to 6–8 days in healthy adults — a phase 1 dose-escalation study with no body-composition endpoint. Gobburu et al. 1999 (PMID 10496658 ^[5]) modeled ipamorelin's PK/PD profile in human volunteers, confirming GH elevation with lower cortisol and prolactin side effects than earlier secretagogues. Neither compound has a published human RCT measuring weight, fat mass, lean mass, or any body-composition outcome. Neither is FDA-approved for any indication.

Evidence summary: agent-by-agent comparison

Why "peptides instead of Ozempic" is mostly marketing

The appeal of the "peptides as an alternative" framing is understandable. GLP-1 drugs are expensive (often $900–$1,400/month without insurance), supply has been constrained, and their side-effect profile — persistent nausea, vomiting, possible muscle mass loss — makes some patients want alternatives. Peptides are positioned to fill that gap: cheaper, injectable, marketed as "more natural" because they mimic endogenous hormones. The logic sounds coherent in abstract. The problem is that it is entirely mechanistic reasoning — "raising GH should mobilize fat" — without the human trial data that would confirm or refute it.

Mechanistic plausibility is not the same as demonstrated efficacy. The history of obesity pharmacology is full of agents that worked beautifully in animal models and failed in human trials — AOD-9604 itself is a case study. Human fat metabolism is far more tightly regulated than rodent fat metabolism, and the doses, duration, and endpoints that generate impressive mouse data frequently do not translate. For a drug to claim it causes weight loss in humans, it needs a human RCT with weight or body composition as a primary endpoint. None of the peptides in the table above meet that standard.

This does not mean these compounds are worthless or that the research is uninteresting. Tesamorelin is a genuinely effective treatment for a specific, real medical condition. BPC-157 has legitimate rodent data for tissue healing and may eventually produce human trial data. The NNMT inhibition mechanism behind 5-Amino-1MQ is an active area of metabolic research. The issue is the claim — specifically that these compounds replace or are equivalent to GLP-1 drugs for weight management. That claim is not supported by any human trial data. Patients who cannot access or tolerate GLP-1 drugs deserve to know this distinction. For a broader review of the peptides sold in this space and what the human evidence shows for each, see our peptide directory and the overview article on peptides for weight loss.

What if you cannot access or tolerate a GLP-1?

If cost, supply, or side effects make GLP-1 drugs inaccessible, the evidence-based alternatives are not peptides — they are the behavioral and pharmacological options that actually have human trial data. Compounded semaglutide (while FDA compound lists permit it) offers a lower-cost access point to the same active molecule — see our guide on the best semaglutide providers for options with independent verification. Orforglipron, an oral GLP-1 receptor agonist in late-stage trials, may expand access by eliminating injection requirements. Dietary patterns (higher-protein, adequate fiber) and resistance training have meaningful, replicated human evidence for both weight and body-composition outcomes. These are not exciting alternatives — but they are the ones with actual supporting trial data.